Article
Becoming a Psychedelic Researcher: Alan Kooi Davis
Why researchers like Alan Kooi Davis — the newest addition to the Johns Hopkins psychedelic research team — decide to devote their careers to studying psychedelics.
Article
Why researchers like Alan Kooi Davis — the newest addition to the Johns Hopkins psychedelic research team — decide to devote their careers to studying psychedelics.
Article
I came to a working hypothesis: at the center of the mystical experience is awe, wherein one is in the presence of something so great, so large, that it requires they completely reorder their mental structures – completely change the way they view reality.
Article
As a teenager, I was taking ten milligrams of Ritalin daily. Later, I grew to love the way these pills made it easier for me not to eat.
Article
Renaming adverse effects of psychedelic drugs as “challenging experiences” minimizes, almost trivializes, their negative effects.
Article
I first discovered the potential psychedelics have for treating stuttering during an experience with psilocybin mushrooms.
Article
Here’s what happened at the first CryptoPsychedelic summit in Tulum, Mexico.
Article
The Ibogaine Conversation Conclusion | The goal of this conversation was to provide a platform for a diverse range of perspectives on a single topic. Not everyone agrees, and that’s the point.
Article
The Ibogaine Conversation Part 10 | Unlike other psychedelic drugs, ibogaine is known to be potentially cardiotoxic. There are a number of fatalities associated with its use, and anyone considering working with it should be aware of the risks.
Article
The Ibogaine Conversation Part 9 | Using ibogaine can be fatal if proper safety precautions aren’t taken.
Article
The Ibogaine Conversation Part 8 | This is not a do-it-at-home type thing.
Article
The Ibogaine Conversation Part 7 | “Prescription is not about accessibility, by definition it’s about restriction. Unless we start to use psychedelics as a way to tear apart these structures and build new ones in their place, then I think it’s all a revolving door.”
Article
The Ibogaine Conversation Part 6 | My experience with heroin went from age 14 up to age 30, and taking ibogaine was as close to a miracle as I have ever experienced in my life.
Psymposia is a research and media 501(c)(3) nonprofit that offers critical perspectives on drugs, politics, and culture.
We rely on audience support to keep our work independent and focused on the public interest. You can sustain Psymposia by becoming a member, which includes exclusive content and perks.